Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
EZZ Life Science Holdings Ltd. ( (AU:EZZ) ) just unveiled an announcement.
EZZ Life Science Holdings reported a challenging December 2025 quarter marked by softer market conditions and heightened competition in China, which drove a 26% year-on-year decline in customer receipts despite a modest improvement on the prior quarter. The company recorded an operating cash outflow of $2.2 million, largely due to significant tax payments and elevated marketing spend ahead of its Australian Open 2026 sponsorship, but underlying cash performance improved versus the prior quarter and EZZ ended the period with $13.5 million in cash and no debt, while also paying a final FY25 dividend. Operationally, EZZ continued to expand its domestic pharmacy footprint with 10 additional Australian stores, bolster brand visibility through major international expos and Australian Open-related events in Shanghai, and maintained leading rankings on Chinese e-commerce platforms during the Double 11 festival. Strategically, the company reshaped its leadership structure by appointing former chair Glenn Cross as Chief Strategy Officer to spearhead its U.S. expansion and strengthening its board with new executive and non-executive directors, including a new non-executive chair to enhance governance and separate board and management roles, while choosing not to proceed with a proposed acquisition to preserve balance sheet flexibility and maintain a prudent capital position.
The most recent analyst rating on (AU:EZZ) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.
More about EZZ Life Science Holdings Ltd.
EZZ Life Science Holdings Ltd is a life science company focused on improving quality of life and human health through the development and distribution of high-quality consumer health products. It operates via omnichannel distribution across Australia, New Zealand, China, the United States and other global markets, with a strong presence in pharmacies and major e-commerce platforms and an emphasis on genomic innovation in its product portfolio.
Average Trading Volume: 57,605
Technical Sentiment Signal: Sell
Current Market Cap: A$86.32M
See more data about EZZ stock on TipRanks’ Stock Analysis page.